Drug Approval | January 23, 2024
EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The workshop was conducted as a part of the NITI–State workshop series
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The company has received five final approvals
Sirius JV will be owned 51% by Sirius and 49% by Adani
US FDA approval based on NEURO-TTRansform Phase III results
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Subscribe To Our Newsletter & Stay Updated
